Drug-free remission: Is it already possible?

Current Opinion in Rheumatology

Volumn 23, Issue 3, 2011, Pages 266-272

  Van Den Broek, Marianne ^a   Huizinga, Tom W J ^a   Dijkmans, Ben A C ^b,c   Allaart, Cornelia F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JAN VAN BREEMEN INSTITUTE   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

drug free; predictors; remission; rheumatoid arthritis; treatment

Indexed keywords

ANALGESIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPITOPE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL RESEARCH; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG DOSE REDUCTION; FINLAND; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; PROGNOSIS; REMISSION INDUCTION; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

EID: 79955037948     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32834563e3     Document Type: Review

References (22)

1. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66:34-45. (Pubitemid 46044858)
2. Brown AK, Conaghan PG, Karim Z, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008; 58:2958-2967.
3. Lichtenstein MJ, Pincus T. Rheumatoid arthritis identified in population based cross sectional studies: low prevalence of rheumatoid factor. J Rheumatol 1991; 18:989-993.
4. Ahern MJ, Hall ND, Case K, Maddison PJ. D-penicillamine withdrawal in rheumatoid arthritis. Ann Rheum Dis 1984; 43:213-217. (Pubitemid 14125185)
5. Cade R, Stein G, Pickering M, et al. Low dose, long-term treatment of rheumatoid arthritis with azathioprine. South Med J 1976; 69:388-392.
6. De Silva M, Hazleman BL. Long-term azathioprine in rheumatoid arthritis: a double-blind study. Ann Rheum Dis 1981; 40:560-563. (Pubitemid 12223264)
7. Kremer JM, Rynes RI, Bartholomew LE. Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy: double-blind study. Am J Med 1987; 82:781-786.
8. Szanto E. Low-dose methotrexate treatment of rheumatoid arthritis; long-term observation of efficacy and safety. Clin Rheumatol 1989; 8:323-420.
9. Van der Leeden H, Dijkmans BA, Hermans J, Cats A. A double-blind study on the effect of discontinuation of gold therapy in patients with rheumatoid arthritis. Clin Rheumatol 1986; 5:56-61. (Pubitemid 16167861)
10. ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996; 347:347-352. (Pubitemid 26046101)
11. Van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Drugfree remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009; 68:914-921.
12. Van der Woude D, Young A, Jayakumar K, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 2009; 60:2262-2271.
13. Tiippana-Kinnunen T, Paimela L, Kautiainen H, et al. Can disease-modifying antirheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up. Scand J Rheumatol 2010; 39:12-18.
14. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24:1308-1315. (Pubitemid 11022943)
15. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Radiographic progression and remission rates in early rheumatoid arthritis: MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the doubleblind randomised CIMESTRA trial. Ann Rheum Dis 2010; 69:1789-1795.
16. Klarenbeek NB,van der KooijSM,Guler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011; 70:315-319.
17. Shammas RM, Ranganath VK, Paulus HE. Remission in rheumatoid arthritis. Curr Rheumatol Rep 2010; 12:355-362.
18. Saleem B, Keen H, Goeb V, et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010; 69:1636-1642.
19. Felson DT, Smolen JS, Wells G, et al. American college of rheumatology/ european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011; 70:404-413;
20. Arthritis Rheum 2011; 63:573-586.
21. Brocq O, Millasseau E, Albert C, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009; 76:350-355.
22. ten Wolde S, Hermans J, Breedveld FC, Dijkmans BA. Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation. Ann Rheum Dis 1997; 56:235-239. (Pubitemid 27239579)